/biz/ - Business & Finance

>>1158804
just looked at their last big earnings jump in 2013, they changed ceo's and added a partnership with quest.
This isn't their first drug
they've been selling ova1 they just got ova2 approved. So they've probably got a manufacturing run and a sales hustle to get it to market.
many questions they need to answer.

The new test seems better but I'd I don't have an oncology lab. Their sales penetration needs to improve.

as of last quarter earnings
27M in cash
~5M burn per quarter
7M research grant on the hook.

The test costs the same as ones on the market $150 but reduces avg patient treatment cost from 33k to 12k if I'm reading these numbers correctly. The other tests are on a 60% firesale on the self testing sites. Looks like they're seizing market share.

So the CEO just completed what she came on to do, and a little extra and added a testing lab to slowly reduce partnership with QUEST who was eating 33% of prior gross.

>>1158847
short term imo
about 21k ova cancer patients per year 15k die
so 6k recurring tests say annually for fudge
plus 500k tests for pelvic lumps.
Their market share is about 1000 tests by the price and sec filings of 1.5M sales and 1500 price

http://vermillion.com/wp-content/uploads/2016/03/VRML-Investor-Deck-03-01-16.pdf

everyone of their board just doubled down on the stock options
http://vermillion.com/investors/sec-filings/

http://www.ovariancancer.org/wp-content/uploads/2014/04/age-and-ethnicity-combo.bmp

Their sales pitch is they're going after the 500k lumps market. that's marketing b/s. doctors and actuaries not stupid. also creatures of habit. That said, boomers avg age 60 median diagnosis age 63. ALL THAT birthcontrol and low fat diets would suggest potential growth of market, thanks hippies. If early diagnosis value proposition is real then, I'd say they're in a decent position to upset a niche market. and it doesn't cost too much in sales these folks will do well. IDARHBWID
WHAT THINKS U?